- Home
- MKTW vs BTAI Comparison
MKTW vs BTAI Comparison
Compare MKTW & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | BTAI |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 35.6M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MKTW | BTAI |
|---|---|---|
| Price | $13.75 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $20.00 | ★ $23.25 |
| AVG Volume (30 Days) | 11.9K | ★ 1.2M |
| Earning Date | 03-06-2026 | 03-20-2026 |
| Dividend Yield | ★ 13.17% | N/A |
| EPS Growth | ★ 1183.33 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.91 | $261.81 |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.17 |
| 52 Week High | $21.74 | $8.08 |
Technical Indicators
Market Signals| Indicator | MKTW | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 48.84 |
| Support Level | N/A | $1.44 |
| Resistance Level | $17.12 | $2.20 |
| Average True Range (ATR) | 0.82 | 0.14 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 9.22 | 38.16 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.